top
Please input keywords
Order
*Country
United States
China
France
Germany
Netherlands
United Kingdom
Japan
South Korea
Israel
Australia
Hong Kong, China
New Zealand
Russia
Singapore
Taiwan, China
India
Aland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua & Barbuda
Argentina
Armenia
Aruba
Ascension Island
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia & Herzegovina
Botswana
Brazil
British Indian Ocean Territory
British Virgin Islands
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Canary Islands
Cape Verde
Caribbean Netherlands
Cayman Islands
Central African Republic
Ceuta & Melilla
Chad
Chile
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo - Brazzaville
Congo - Kinshasa
Cook Islands
Costa Rica
Côte d’Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czechia
Denmark
Diego Garcia
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands
Faroe Islands
Fiji
Finland
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Honduras
Hungary
Iceland
Indonesia
Iran
Iraq
Ireland
Isle of Man
Italy
Jamaica
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Kosovo
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macau, China
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar (Burma)
Namibia
Nauru
Nepal
New Caledonia
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
North Korea
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territories
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn Islands
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Rwanda
Samoa
San Marino
São Tomé & Príncipe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Sint Maarten
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia & South Sandwich Islands
South Sudan
Spain
Sri Lanka
St. Barthélemy
St. Helena
St. Kitts & Nevis
St. Lucia
St. Martin
St. Pierre & Miquelon
St. Vincent & Grenadines
Sudan
Suriname
Svalbard & Jan Mayen
Swaziland
Sweden
Switzerland
Syria
Tajikistan
Tanzania
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad & Tobago
Tristan da Cunha
Tunisia
Turkey
Turkmenistan
Turks & Caicos Islands
Tuvalu
U.S. Outlying Islands
U.S. Virgin Islands
Uganda
Ukraine
United Arab Emirates
United Nations
Uruguay
Uzbekistan
Vanuatu
Vatican City
Venezuela
Vietnam
Wallis & Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
*Province
*City
*Name
*Telephone
*Company
*Position
*Email
*Verification code
*Verification Code
B-NDG B2m KO mice plus
Strain Name 

B-NDG-B2mtm1 Fcrntm1(mB2m)Bcgen/Bcgen

Common Name 

B-NDG B2m KO mice plus

Background B-NDG Catalog number  110601
Related Genes 

B2m (beta-2 microglobulin) ;
Fcgrt (Fc receptor, IgG, alpha chain transporter,as known as Fcrn)

NCBI Gene ID
12010,14132

Mice Description



Human PBMC-engrafted humanized mice are attractive models for in vivo analysis of human immune responses. We previously reported that human PBMCs could be engrafted in B-NDG mice successfully. However, because of severe xenogeneic graft versus host disease (xeno-GVHD) in these mice, there is a limited window for experiments. The onset of GvHD is directly related to the degree of engraftment of human T cells. The mismatches between human and mouse MHCs are the main cause of GvHD after human PBMC transplantation1. Data have shown that knockout of MHC class I and/or II molecules in mice attenuates GvHD and prolongs the window period for experiments after human PBMC transplantation.

MHC class I molecules consist of two subunits, α and β chains. The B2m (beta-2-microglobulin) gene encodes the β chain. Knockout of the B2m gene in mice can result in the inability to form intact MHC class I molecules and cannot be expressed on the cell surface to exert antigen presentation, thereby alleviating GvHD. However, B2M is also a subunit of FcRn, the Fc receptor for IgG. The structure of FcRn is similar to that of MHC class I molecules, consisting of the α chain encoded by the Fcgrt gene and the β chain encoded by the B2m gene. FcRn can bind to antibodies and prolong the half-life of antibodies. Loss of B2M expression results in a shortened half-life of the antibody in mice.

Biocytogen developed the B-NDG B2m KO plus mice, which knocked out the mouse B2m gene, while the mouse B2m and Fcrgt fusion gene were knocked in at the mouse Fcgrt gene locus. This mouse has a background of B-NDG mice and does not express MHC class I molecules on the cell surface. Compared with B-NDG mice, this mouse has no difference in the metabolism of IgG and is effective in delaying the development of GvHD. This model can be used to investigate the in vivo mechanism of xenogeneic graft versus host disease (GvHD) and to evaluate the efficacy of antitumor drugs using humanized mice reconstituted with human PBMCs.



Expression analysis of MHC class l molecules



from clipboard



Expression of MHC class I in B-NDG B2m KO plus mice

Blood cells, splenocytes, bone marrow cells were respectively collected from B-NDG B2m KO plus mice, B-NDG mice, NOD scid mice (n=5). Expression of MHC class I (H-2Kb) was analyzed with FACS. Results showed that MHC class I molecule was detectable in B-NDG mice and NOD scid mice. But there was no MHC class I molecule detectable in B-NDG B2m KO plus mice.



Expression analysis of MHC class II molecules



from clipboard


Expression of MHC class II in B-NDG B2m KO plus mice

Blood cells, splenocytes, bone marrow cells were respectively collected from B-NDG B2m KO plus mice, B-NDG mice, NOD scid mice (n=3). Expression of MHC class II (I-AK) was analyzed with FACS. Results showed that the MHC class II molecules were all detectable in dendritic cells and macrophages of the three strains of mice.



Flow cytometric analysis of T , B and NK cells


from clipboard


Blood cells, splenocyte, cells were collected from B-NDG B2m KO  plus, B-NDG, NOD-scid and C57BL/6 mice (n=5) and analyzed by flow cytometry with T, B and NK cells. T, B and NK cells were not detectable in B-NDG B2m KO  plus and B-NDG mice. T, B cells were undetectable and NK cells were detectable in NOD scid mice. T, B and NK cells were detectable in C57BL/6 mice.


Flow cytometric analysis of Macrophages


from clipboard


Blood cells, splenocyte, Bone marrow cells were collected from B-NDG B2m KO  plus, B-NDG, NOD-scid and C57BL/6 mice (n=5) and analyzed by flow cytometry with Macrophages(mCD45+mCD11b+mF4-80+). Macrophages were detectable in B-NDG B2m KO  plus, B-NDG, NOD-scid and C57BL/6 mice.


Flow cytometric analysis of DC cells and monocytes


from clipboard


Blood cells, splenocyte, Bone marrow cells were collected from B-NDG B2m KO  plus, B-NDG, NOD-scid and C57BL/6 mice (n=5) and analyzed by flow cytometry with DC cells (mCD45+mCD11b+mCD11c) and monocytes (mCD45+mCD11b+mLy6c). DC cells and monocytes were detectable in B-NDG B2m KO  plus, B-NDG, NOD-scid and C57BL/6 mice.


Histopathological sections of tissues from B-NDG B2m KO mice plus and control mice



Histopathological sections of tissues from B-NDG B2m KO mice plus and control mice.

(A) Spleen from C57BL/6 has normal structure with well-defined follicles. (B) Spleen from NOD-scid show hypoplasia of  white pulp. (C, D) Spleen from both B-NDG and B-NDG B2m KO mice plus show complete loss of follicular structure. (E) Thymic lobes from C57BL/6 have normal structure with a well-defined cortex. (F) Thymic lobes from NOD-scid mice are hypoplastic and lack a defined cortex.(g) Thymic lobes from B-NDG mice are severely hypoplastic and lack a defined cortex. (H) B-NDG B2m KO mice plus show no thymic lobes on the normal anatomy location.


PK analysis of human IgG in serum



from clipboard


The PK of human IgG in B-NDG B2m KO mice plus was similar to that in wild-type mice.

B-NDG, B-NDG B2m KO mice, B-NDG B2m KO mice plus and C57BL/6 mice were treated with human IgG (n=5). Blood samples were collected at different time point for the PK assay. Results showed that the PK of B-NDG mice and B-NDG B2m KO mice plus groups were basically in line with the pharmacokinetic characteristics, with no difference compared with wild-type C57BL/6 mice, and the drug concentration of B-NDG B2m KO mice group could not be measured at the time point 2 days later.



Effectively delayed the onset of GvHD induced by human PBMC engraftment



from clipboard 


B-NDG B2m KO mice plus can effectively delay the onset and reduce the severity of GvHD induced by human PBMC engraftment.

B-NDG B2m KO plus mice (n = 5, female, 11-week-old) and B-NDG mice (n = 6, female, 10-week-old) were injected intravenously with human PBMCs (2E7) from three healthy donors on day 0, and each mouse was scored twice weekly for clinical signs according to GvHD scoring criteria. The results showed that B-NDG B2m KO plus mice could significantly prolong the survival time, delay the occurrence and reduce the severity of GvHD compared with B-NDG mice in the GvHD model constructed after human PBMC transplantation.



B-NDG B2m KO mice plus are well suited for human immune system engraftment




B-NDG B2m KO mice plus are well suited for human immune system engraftment.

Human PBMC (5E6) were intravenous implanted into homozygote B-NDG B2m KO mice plus and  B-NDG mice (female, 7-week-old, n=6). Representative flow cytometric analysis of PBMCs from mice after engraftment with human PBMC.B-NDG B2m KO mice plus show a little change in body weight and exhibit longer survival compared with B-NDG. The result showed that human PBMC engrafted humanized mice model was successfully constructed.


Anti-tumor efficacy in PBMC RKO model in B-NDG B2m KO mice plus


from clipboard


Antitumor activity of the combination of pembrolizumab (anti PD-1) and ipilimumab (anti CTLA4) in B-NDG B2m KO mice plus reconstituted with hPBMCs.

Human colon cancer RKO cells (5E6) were subcutaneously implanted after human PBMCs (1E7) injected into B-NDG B2m KO mice plus (n=7/8). Mice were grouped when tumor volume reached approximately 100-150 mm3. Anti-human PD-1 antibody and anti-human CTLA4 antibody (in house) were injected intraperitoneally. The results showed that combination of anti-hPD-1 antibody and anti-CTLA4 antibody can effectively inhibited the tumor growth, indicating that B-NDG B2m mice plus reconstituted with PBMCs provides a powerful preclinical model for in vivo evaluation of antibodies. Values are expressed as mean ± SEM.




In vivo efficacy of CAR-T can be effectively evaluated in B-NDG B2m KO mice plus


from clipboard


A human lung cancer model was established by implanting NCI-H226 into B-NDG B2m KO plus mice, which can effectively evaluate the in vivo efficacy of CAR-T therapy.

Human lung cancer cells NCI-H226 (1E7) were implanted into B-NDG B2m KO mice plus. Mice were grouped when tumor volume reached approximately 150±50 mm3, at which time they were treated with CAR-T cells (5E5) with schedules indicated in panel. (A) Tumor volume. (B) Body weight changes during treatment. The results showed that CAR-T cells differently inhibited tumor growth in B-NDG B2m KO mice plus. Within 5 weeks of CAR-T treatment, the body weight of mice in the treatment groups continued to increase without significant GvHD.



Bispecific antibody in vivo efficacy evaluation in B-NDG B2m mice plus reconstituted with human PBMCs

Figure 12. B-NDG B2m mice plus reconstituted with PBMCs were used for anti PD-1×PD-L1 bispecific antibody efficacy studies 
RKO cells (5E6) were subcutaneously implanted after human PBMCs (5E6) implanted into B-NDG B2m mice plus (female, 9 week-old, n=6). The animals were grouped into control and treatment when the tumor size was approximately 100 mm3. (A) Anti human PD-1×PD-L1 bispecific antibody inhibited RKO tumor growth in human PBMC reconstituted B-NDG B2m mice plus. (B) Body weight changes during treatment. Anti PD-1×PD-L1bispecific antibody shows significant tumor inhibitory effects. The results indicate that B-NDG B2m mice plus reconstituted with PBMCs provides a powerful preclinical model for in vivo evaluation of  antibodies. Values are expressed as mean ± SEM.


Summary

  1. Flow cytometric analysis of MHC class l and Il expression.  MHC class I were not detectable in B-NDG B2m KO mice plus .
  2. Flow cytometric analysis using specific markers for T, B and NK cells. T, B and NK cells were not detectable in B-NDG B2m KO  plus.
  3. Determination of plasma concentrations of human IgG in different mice .The results showed that the PK results of B-NDG and B-NDG B2m KO mice plus groups were basically in line with the pharmacokinetic characteristics, with no difference compared with wild-type mice Physiological function
  4. B-NDG B2m KO mice plus are well suited for human immune system engraftment. Human PBMC (5E6) were intravenous implanted into homozygote B-NDG B2m KO mice plus and B-NDG mice (female, 7-week-old, n=6). Representative flow cytometric analysis of PBMCs from mice after engraftment with human PBMC. B-NDG B2m KO mice plus show a little change in body weight and exhibit longer survival compared with B-NDG.